The Protection of Thyroid Function in IMRT for Nasopharyngeal Carcinoma

Launched by JIANGXI PROVINCIAL CANCER HOSPITAL · Feb 13, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on protecting the thyroid gland from damage caused by radiation treatment for nasopharyngeal carcinoma, a type of cancer located in the area behind the nose. The researchers aim to improve the way radiation is delivered to minimize harm to the thyroid while still effectively targeting the cancerous lymph nodes in the neck. This study is currently looking for participants aged 18 to 70 who have been newly diagnosed with a specific type of nasopharyngeal cancer and meet certain health criteria, such as not having any prior thyroid issues or other cancers.

Participants in this trial can expect to receive advanced radiation therapy designed to treat their cancer while also taking steps to protect their thyroid function. To be eligible, individuals must be in good overall health, have certain blood test results within a normal range, and agree to sign a consent form. This trial is important because it could lead to better treatment options for nasopharyngeal cancer patients by reducing the risk of developing thyroid problems later on.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. The pathological diagnosis was newly diagnosed non-keratinizing squamous cell carcinoma nasopharyngeal carcinoma.
• • 2. The clinical stage is T1-4N0-3M0 (stage I\~IVa, UICC/AJCC 8th edition);
• • 3. There is no history of hypothyroidism or hyperthyroidism before treatment;
• • 4. Using intensity-modulated radiotherapy technology,
• • 5. Complete radical dose radiotherapy;
• • 6. KPS≥70 points;
• • 7. Age 18-70 years old;
• • 8. Male or female who is not pregnant or lactating;
• • 9. Hematological examination: white blood cells \> 4×109/L, neutrophils \> 2×109/L, hemoglobin \> 90g/L, platelets \> 100×109/L;
• • 10. Liver function: ALT, AST \< 1.5×ULN, ALP \< 2.5×ULN, bilirubin \< ULN.
• • 11. Renal function: creatinine \> 60 ml/min;
• • 12. The patient signs the informed consent form;
• Exclusion Criteria:
• • 1. WHO pathological classification is keratinizing squamous cell carcinoma or basaloid carcinoma;
• • 2. palliative treatment;
• • 3. Have a history of other malignant tumors;
• • 4. Pregnant or lactating women (women of childbearing age should consider taking a pregnancy test, and patients are required to use effective contraception during treatment);
• • 5. Have a history of neck surgery;
• • 6. Have a history of hyperthyroidism or hypothyroidism.
• • 7. Previous history of head and neck radiation therapy;